Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2010

View Archived Issues

Clinical and preclinical data suggest potential of teneligliptin in diabetes

Elan Pharma reports effects of ELND-006 on Abeta in animals

Encouraging data disclosed on antidiabetes candidate TAK-875

Biolipox claims new LTC4 synthase inhibitors

Korean scientists disclose new inhibitors of Abeta neurotoxicity

Merck & Co. describes novel GPR109B receptor agonists

Novel HIF-1-alpha activators identified by sanofi-aventis

ABT-288 improves cognition in vivo

SAM-760 under clinical evaluation for treatment of AD

Clinical data on inhaled Technosphere insulin disclosed at ADA

FDA approves Lorus Therapeutics' IND for anticancer agent LOR-253

Watson Pharma licenses Itero's rFSH for female infertility

Health Canada clears phase III ReoT3D trial in head and neck cancer

Almirall presents novel S1P1 receptor agonists

Jevtana launched in U.S. for metastatic hormone-refractory prostate cancer

FDA approves Veltin gel for acne vulgaris in patients age 12 years and older

Takeda's Lampion pack approved in Japan

Geron begins phase II imetelstat trial in advanced non-small cell lung cancer

Phase II trial of interferon alfa-n3 for flu cleared in India

FDA begins NDA review for new oral rufinamide formulation

Tenofovir vaginal gel progresses in clinical trials for HIV prevention

Pfizer suspends tanezumab trials in chronic pain at request of FDA

Actelion's option to acquire Trophos depends on phase III olesoxime data

FLAP inhibitors enter phase II studies in asthma

Pharming finalizes divestment of DNage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...